시장보고서
상품코드
2108385

생체 내 독성학 시장 분석 및 예측(-2035년) : 유형, 제품, 서비스, 기술, 용도, 프로세스, 최종 사용자, 시행 형태

In Vivo Toxicology Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Mode

발행일: | 리서치사: 구분자 Global Insight Services | 페이지 정보: 영문 350 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 4,750 금액 안내 화살표 ₩ 6,651,000
PDF & Excel (Site License) help
PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.
US $ 5,750 금액 안내 화살표 ₩ 8,052,000
PDF & Excel (Enterprise License) help
PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 6,750 금액 안내 화살표 ₩ 9,452,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 생체 내 독성학 시장은 2025년 65억 달러에서 2035년까지 117억 달러로 확대되어 CAGR은 6.1%를 나타낼 것으로 예측됩니다. 생체 내 독성학 시장은 의약품 개발 활동의 활성화, 안전성 평가에 관한 규제 요건의 강화, 의약품 및 생물학적 제제의 비임상시험에 대한 수요 증가에 힘입어 성장하고 있습니다. 미국 식품의약국(FDA) 의약품평가연구센터(CDER)의 2024년 보고서에 따르면, FDA는 2024년에 50건의 신약을 승인했습니다. 이러한 승인은 규제 당국의 심사를 뒷받침하기 위해 필요한 비임상 개발 프로그램의 핵심 요소로서, 종합적인 독성 시험의 중요성을 부각시키고 있습니다.

생체 내 독성학 시장의 ‘유형’ 부문에는 급성 독성 시험, 아만성 독성 시험, 만성 독성 시험, 발암성 시험, 발생·생식 독성 시험 등이 포함됩니다. 이 중 급성 및 만성 독성 검사는 의약품, 화학물질 및 기타 생물학적 제제의 안전성 프로파일을 평가하는 데 필수적인 역할을 수행하고 있어 큰 시장 점유율을 차지하고 있습니다. 급성 독성 시험은 즉각적인 유해 작용을 평가하기 위한 초기 단계 조사에서 널리 활용되는 반면, 만성 독성 시험은 규제 당국의 승인을 위한 장기적인 안전성 평가를 뒷받침합니다. 또한, 치료제나 화학물질이 생식 건강 및 발육 결과에 미치는 영향에 대한 평가에 규제 당국의 관심이 높아짐에 따라, 발생·생식 독성 시험의 중요성도 커지고 있습니다.

생체 내 독성학 시장의 용도 부문에는 제약, 생명공학, 화장품, 화학 산업, 식품 산업 등이 포함됩니다. 신약 개발 및 개발 과정에서 전임상 안전성 평가에 대한 수요가 증가함에 따라, 제약 산업이 주요 용도 부문을 차지하고 있습니다. 생명공학 기업들은 생물학적 제제, 유전자 치료, 첨단 치료법의 평가를 위해 생체 내 독성학의 활용을 확대되고 있습니다. 화장품 산업과 화학 산업에서는 제품의 안전성과 규제 준수를 확보하기 위해 독성 검사를 활용하고 있으며, 식품 산업에서는 식품 첨가물 및 원료 평가에 이러한 검사를 적용하고 있습니다. 규제 요건의 강화와 연구 개발에 대한 투자 확대가 모든 용도에 걸친 시장 성장을 더욱 뒷받침하고 있습니다.

지역별 개요

2025년, 북미는 강력한 제약·바이오기술 부문, 첨단 전임상 연구 인프라, 의약품 안전성 평가에 대한 엄격한 규제 요건에 힘입어 전 세계 생체 내 독성학 시장에서 가장 큰 점유율을 차지했습니다. 이 지역에는 임상시험에 앞서 의약품, 바이오의약품, 화학물질, 의료기기의 안전성을 평가하기 위해 생체 내 독성학을 폭넓게 활용하고 있는 주요 수탁 연구 기관(CRO), 제약 기업, 연구 기관이 거점을 두고 있습니다. 신약 개발에 대한 막대한 투자, 생물학적 제제 및 유전자 치료 개발 확대, 정부 기관의 강력한 자금 지원이 시장 성장을 더욱 뒷받침하고 있습니다. 또한, 첨단 영상 기술의 도입, 표준화된 검사 프로토콜, 고품질 실험 시설의 구축이 세계 생체 내 독성학 시장에서 북미의 선도적 지위를 더욱 공고히 하고 있습니다.

아시아태평양에서는 제약 및 생명공학 연구 확대, 전임상시험의 아웃소싱 증가, 그리고 실험실 인프라에 대한 투자 확대로 인해 생체독성학 시장에서 가장 높은 성장이 예상됩니다. 중국, 인도, 일본, 한국 등의 국가들은 정부의 지원, 계약연구기관(CRO)의 성장, 의약품 개발 활동의 확대를 통해 전임상 연구 역량을 강화하고 있습니다. 낮은 운영 비용, 숙련된 연구자 확보, 임상 및 전임상 연구 간의 협력 증대로 인해 이 지역은 전 세계 제약 기업들에게 매력적인 거점이 되고 있습니다. 또한, 신약, 생물학적 제제, 바이오시밀러에 대한 안전성 평가 수요 증가와 규제 체계의 지속적인 개선이 더해지면서, 예측 기간 동안 아시아태평양 전체에서 견조한 시장 성장이 이끌어질 것으로 전망됩니다.

주요 동향 및 성장 촉진요인

대체 및 첨단 생체 내 독성학 모델의 채택 확대

생체 내 독성학 시장에서는 안전성 평가의 정확도를 높이기 위해 첨단 동물 모델, 유전자 변형 모델, 통합적인 검사 기법의 채택이 확대되는 추세를 보이고 있습니다. 제약 회사와 생명공학 기업들은 전임상 개발 단계에서 약물의 독성, 약동학, 장기적인 안전성 프로파일을 평가하기 위해 첨단 생체 내 검사를 점점 더 많이 활용하고 있습니다. 분자생물학, 바이오마커 분석, 영상 기술의 발전으로 인해 더 초기 단계에서 독성 작용을 감지하는 능력이 향상되고 있습니다. 또한, 인공지능 및 예측 독성 평가 도구의 통합을 통해 보다 효율적인 시험 설계와 데이터 분석이 가능해지면서, 의약품 개발 프로그램 내 의사 결정이 개선되고 있습니다.

제약 연구개발 활동의 활성화와 의약품 개발 파이프라인의 확대

지속적으로 확대되고 있는 제약 및 생명공학 연구 파이프라인은 생체 내 독성학 시장의 주요 성장 촉진요인으로 작용하고 있습니다. 바이오의약품, 유전자 치료, 세포 치료, 신규 저분자 의약품의 개발이 증가함에 따라, 임상시험에 앞서 광범위한 전임상 안전성 평가가 요구되고 있습니다. 신약 개발에 대한 투자 확대, 만성 질환 유병률의 상승, 효과적인 치료법에 대한 수요 증가는 기업들이 종합적인 독성 검사를 실시하도록 부추기고 있습니다. 인간을 대상으로 한 시험에 앞서 의약품의 안전성과 유효성을 평가해야 한다는 규제 요건으로 인해, 생체 내 독성학 서비스 및 모델에 대한 수요는 더욱 높아지고 있습니다. 또한, 전문적인 독성 검사를 제공하는 계약 연구 기관(CRO)의 성장도 시장 확대를 뒷받침하고 있습니다.

목차

제1장 주요 요약

제2장 시장 하이라이트

제3장 시장 역학

제4장 부문별 분석

제5장 지역별 분석

제6장 시장 전략

제7장 경쟁 정보

제8장 기업 개요

제9장 회사 소개

KTH 26.08.20

The global In Vivo Toxicology Market is projected to grow from $6.5 billion in 2025 to $11.7 billion by 2035, at a compound annual growth rate (CAGR) of 6.1%. The in vivo toxicology market is driven by increasing drug development activities, rising regulatory requirements for safety evaluation, and growing demand for preclinical testing of pharmaceuticals and biologics. According to the U.S. FDA Center for Drug Evaluation and Research (CDER) 2024 report, the FDA approved 50 novel drugs in 2024. These approvals underscore the importance of comprehensive toxicology studies as a key component of the nonclinical development program needed to support regulatory review.

The Type segment of the In Vivo Toxicology Market includes acute toxicity testing, sub-chronic toxicity testing, chronic toxicity testing, carcinogenicity testing, developmental and reproductive toxicity testing, and others. Among these, acute and chronic toxicity testing hold significant market shares due to their essential role in evaluating the safety profiles of drugs, chemicals, and other biological products. Acute toxicity testing is widely used in early-stage research to assess immediate adverse effects, while chronic toxicity testing supports long-term safety evaluation for regulatory approvals. Developmental and reproductive toxicity testing is gaining importance due to increasing regulatory emphasis on assessing the impact of therapeutics and chemicals on reproductive health and developmental outcomes.

Market Segmentation
TypeAcute Toxicity Testing, Sub-chronic Toxicity Testing, Chronic Toxicity Testing, Carcinogenicity Testing, Developmental and Reproductive Toxicity Testing, Others
ProductAnimal Models, Reagents & Kits, Instruments, Software, Others
ServicesConsulting Services, Testing Services, Data Analysis Services, Others
TechnologyCRISPR, RNA Interference, Transgenic Models, Others
ApplicationPharmaceuticals, Biotechnology, Cosmetics, Chemical Industry, Food Industry, Others
ProcessIn Vivo Imaging, In Vivo Screening, Others
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations, Others
ModeIn-house Testing, Outsourced Testing, Others

The Application segment of the In Vivo Toxicology Market includes pharmaceuticals, biotechnology, cosmetics, chemical industry, food industry, and others. Pharmaceuticals represent the leading application segment due to the increasing requirement for preclinical safety assessments during drug discovery and development processes. Biotechnology companies are expanding their use of in vivo toxicology studies for evaluating biologics, gene therapies, and advanced therapeutics. The cosmetics and chemical industries utilize toxicology testing to ensure product safety and regulatory compliance, while the food industry applies these studies for evaluating food additives and ingredients. Growing regulatory requirements and rising investments in research and development are further supporting market growth across applications.

Geographical Overview

North America accounted for the largest share of the global in vivo toxicology market in 2025, driven by its strong pharmaceutical and biotechnology sectors, advanced preclinical research infrastructure, and stringent regulatory requirements for drug safety evaluation. The region is home to leading contract research organizations (CROs), pharmaceutical companies, and research institutions that extensively utilize in vivo toxicology studies for assessing the safety of drugs, biologics, chemicals, and medical devices before clinical trials. Significant investments in drug discovery, increasing development of biologics and gene therapies, and strong funding from government agencies have further supported market growth. Additionally, the adoption of advanced imaging technologies, standardized testing protocols, and high-quality laboratory facilities continues to reinforce North America's leadership in the global in vivo toxicology market.

Asia Pacific is expected to witness the highest growth in the in vivo toxicology market due to expanding pharmaceutical and biotechnology research, increasing outsourcing of preclinical studies, and rising investments in laboratory infrastructure. Countries such as China, India, Japan, and South Korea are strengthening their preclinical research capabilities through government support, growing contract research organizations, and expanding drug development activities. Lower operational costs, availability of skilled researchers, and increasing clinical and preclinical research collaborations have made the region an attractive destination for global pharmaceutical companies. Furthermore, rising demand for safety testing of novel therapeutics, biologics, and biosimilars, along with continuous improvements in regulatory frameworks, is expected to drive robust market growth across Asia Pacific during the forecast period.

Key Trends and Drivers

Increasing Adoption of Alternative and Advanced In Vivo Toxicology Models:

The In Vivo Toxicology Market is witnessing a growing trend toward the adoption of advanced animal models, genetically modified models, and integrated testing approaches to improve the accuracy of safety assessments. Pharmaceutical and biotechnology companies are increasingly using sophisticated in vivo studies to evaluate drug toxicity, pharmacokinetics, and long-term safety profiles during preclinical development. Advances in molecular biology, biomarker analysis, and imaging technologies are enhancing the ability to detect toxicological effects at earlier stages. Additionally, the integration of artificial intelligence and predictive toxicology tools is supporting more efficient study design and data interpretation, improving decision-making in drug development programs.

Rising Pharmaceutical R&D Activities and Increasing Drug Development Pipeline:

The expanding pharmaceutical and biotechnology research pipeline is a major driver of the In Vivo Toxicology Market. The increasing development of biologics, gene therapies, cell therapies, and novel small-molecule drugs requires extensive preclinical safety evaluation before clinical trials. Growing investments in drug discovery, rising prevalence of chronic diseases, and increasing demand for effective therapies are encouraging companies to conduct comprehensive toxicology studies. Regulatory requirements for assessing drug safety and efficacy before human testing further increase the need for in vivo toxicology services and models. Additionally, the growth of contract research organizations (CROs) offering specialized toxicology testing is supporting market expansion.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Acute Toxicity Testing
    • 4.1.2 Sub-chronic Toxicity Testing
    • 4.1.3 Chronic Toxicity Testing
    • 4.1.4 Carcinogenicity Testing
    • 4.1.5 Developmental and Reproductive Toxicity Testing
    • 4.1.6 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Animal Models
    • 4.2.2 Reagents & Kits
    • 4.2.3 Instruments
    • 4.2.4 Software
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting Services
    • 4.3.2 Testing Services
    • 4.3.3 Data Analysis Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR
    • 4.4.2 RNA Interference
    • 4.4.3 Transgenic Models
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Pharmaceuticals
    • 4.5.2 Biotechnology
    • 4.5.3 Cosmetics
    • 4.5.4 Chemical Industry
    • 4.5.5 Food Industry
    • 4.5.6 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Contract Research Organizations
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 In Vivo Imaging
    • 4.7.2 In Vivo Screening
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 In-house Testing
    • 4.8.2 Outsourced Testing
    • 4.8.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Charles River Laboratories
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Envigo
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Labcorp Drug Development
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Eurofins Scientific
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 WuXi AppTec
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Covance
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Thermo Fisher Scientific
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 BASF SE
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 BioReliance
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Harlan Laboratories
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Cyprotex
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 MB Research Laboratories
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Toxikon Corporation
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 The Jackson Laboratory
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Taconic Biosciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Inotiv
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Genentech
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Pfizer
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Merck KGaA
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 AstraZeneca
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기